Division of Hematology and Medical Oncology, Department of Internal Medicine, Ellis Fischel Cancer Center/University of Missouri School of Medicine, Columbia, 65203, USA.
Am J Med Sci. 2011 Mar;341(3):253-6. doi: 10.1097/MAJ.0b013e31820375be.
Acquired factor V inhibitor is a rare but potentially life-threatening hemorrhagic disorder caused by the development of autoantibodies directed against coagulation factor V. The management of acute bleeding and inhibitor eradication is the mainstay of the treatment. The authors report a case of a 79-year-old man who underwent right hip arthroplasty and postoperatively, when on Coumadin for deep venous thrombosis prophylaxis, developed bleeding from the surgical site with a hematoma and abnormal coagulation parameters. Further workup revealed an acquired factor V inhibitor. The approach to treat this rare and challenging disorder is discussed. The patient responded rapidly with disappearance of factor V inhibitor titers after initiation of treatment with rituximab, prednisone and cyclophosphamide.
获得性因子 V 抑制剂是一种罕见但可能危及生命的出血性疾病,由针对凝血因子 V 的自身抗体的发展引起。急性出血和抑制剂消除的管理是治疗的主要方法。作者报告了一例 79 岁男性,他接受了右髋关节置换术,术后因深静脉血栓形成预防而使用华法林,手术部位出现血肿和凝血参数异常的出血。进一步的检查显示获得性因子 V 抑制剂。讨论了治疗这种罕见且具有挑战性的疾病的方法。该患者在接受利妥昔单抗、泼尼松和环磷酰胺治疗后,因子 V 抑制剂滴度迅速消失,病情迅速缓解。